KALAMAZOO, Mich., Sept. 24, 2013 /PRNewswire/ -- Honigman Miller Schwartz and Cohn LLP represented Sunshine Heart, Inc. (Nasdaq: SSH), a Minneapolis-based global medical technology company, in its public offering of 3,810,000 shares of its common stock with a 30-day option for the underwriters to purchase up to an additional 15 percent of the shares of common stock offered in the public offering solely to cover over-allotments, if any. The offering closed today.

Phillip D. Torrence, a partner in the firm's Corporate Department and leader of its Corporate and Securities and Financial Institutions Practice Groups, was the lead attorney advising on this offering. He was assisted by Honigman attorneys Melanie Van Antwerp, Justin Crawford and Jeff Kuras.

"Honigman's guidance has been invaluable to Sunshine Heart, Inc. during this monumental milestone in our history," said Dave Rosa, Sunshine Heart's CEO and President. "This offering provides us with funds to further advance our pivotal trial and post-market EU study and our initial commercialization activities."

Piper Jaffray & Co. and Cowen and Company, LLC acted as joint book-running managers and Lazard Capital Markets LLC acted as co-lead manager for the offering. Craig-Hallum Capital Group and Northland Securities, Inc. acted as co-managers for the offering.

About Honigman Honigman is a leading business law firm based in Michigan with an international practice. Headquartered in Detroit with offices in Lansing, Oakland County, Ann Arbor and Kalamazoo, the firm has attorneys practicing in more than 50 different areas of concentration. Honigman's highly credentialed attorneys and staff, along with its customer-service focus, provide clients in a wide variety of industries timely and cost-effective counsel.

Honigman is proud to be named among the "101 Best and Brightest Companies to Work For," the Detroit Free Press "Top Workplaces," and the "50 Best Law Firms for Women." For more information about Honigman visit www.honigman.com .

About Sunshine® Heart Sunshine Heart, Inc. (Nasdaq: SSH) is a medical device company focused on developing, manufacturing and commercializing the C-Pulse System for treatment of Class III and ambulatory Class IV heart failure. Sunshine Heart has completed an approved U.S. Food and Drug Administration (FDA) feasibility clinical trial of the C-Pulse System and presented the results in November 2011. In March 2012, the FDA notified the Company that it could move forward with an investigational device exemption (IDE) application. Sunshine Heart received unconditional approval from the FDA in November 2012 to initiate its pivotal trial. In July 2012 Sunshine Heart received CE Mark approval for its C-Pulse System in Europe. Sunshine Heart is a Delaware corporation headquartered in Minneapolis with a wholly owned subsidiary in Australia. The Company has been listed on the NASDAQ Capital Market since February 2012.

SOURCE Honigman Miller Schwartz and Cohn LLP

RELATED LINKS http://www.honigman.com